Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Cervical Ca PROs in Clinical Practice

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
リンクがクリップボードに保存されます
状態アクティブ、募集していない
スポンサー
University Health Network, Toronto

キーワード

概要

Concurrent chemo-radiotherapy followed by intracavitary brachytherapy is standard of care for patients with locally advanced cervical cancer. Although curative, this treatment is challenging and leaves a significant proportion of women with severe toxicity, negatively impacting their quality of life. Although most recover over time, a proportion of women do not. Therefore, evaluation of quality of life becomes increasingly more important as cancer specific outcomes improve. One such method is through patient-reported outcomes (PROs), defined as "any report coming directly from the patient about a health condition and its treatment." This prospective multi-institutional study, involving the Princess Margaret (PM), Odette Regional Cancer Centre(ORCC) and Royal Victoria Regional Health Center (RVH), will assess to feasibility and acceptability of integrating a cervical cancer specific PRO measurement tool into clinical practice. Cervical cancer patients coming for follow-up appointments will be asked to complete the EORTC QLQ-CX24, a validated cervical cancer specific PRO questionnaire. At the end of the study period, Feedback Forms will be completed by participating patients and health care providers to obtain their perspectives regarding the feasibility and acceptability of incorporating the instrument into clinical practice. Future directions include designing an electronic platform and expanding its use in cervical cancer clinics provincially and nationally. The data collected should help identify disease-related symptoms, treatment-related toxicities, facilitate patient-physician communication, shared treatment planning and target intervention strategies.

日付

最終確認済み: 03/31/2019
最初に提出された: 02/06/2017
提出された推定登録数: 02/06/2017
最初の投稿: 02/08/2017
最終更新が送信されました: 04/23/2019
最終更新日: 04/24/2019
実際の研究開始日: 02/26/2017
一次完了予定日: 10/31/2020
研究完了予定日: 10/31/2020

状態または病気

Cervical Cancer
Radiation Therapy

介入/治療

Other: Cervical Cancer Patients

Other: Oncologist

段階

-

アームグループ

介入/治療
Cervical Cancer Patients
Adult, English-speaking cervical cancer patients, who have been treated with curative intent chemo-radiotherapy.
Other: Cervical Cancer Patients
Disease specific Patient Reported Outcome measurement tool developed by the European Organization for Research and Treatment of Cancer (EORTC). This questionnaire covers symptoms common to women with cervical cancer and captures the impact of disease and/or treatment on domains including: urologic and gastro-intestinal symptoms, sexual functioning and body image.
Oncologist
Oncologists who treat cervix cancer, with at least one consenting patient enrolled in the study.
Other: Oncologist
This Feedback form to be completed by oncologists who have had at least one consenting patient participating in this study.

適格基準

研究の対象となる年齢 18 Years に 18 Years
研究に適格な性別All
サンプリング方法Non-Probability Sample
健康なボランティアを受け入れるはい
基準

Patient Inclusion Criteria:

1. Adult (> 18 years) English speaking patients

2. Treated with curative intent with chemo-radiotherapy

3. Seen in routine clinic follow-up within 5 years post completion of treatment

Patient Exclusion Criteria:

1. Patients at their anticipated last clinic visit prior to cancer center discharge

2. Patients unable to complete the EORTC QLQ CX-24 questionnaire due to inability to read or write.

3. Non-English speaking patients

4. Patients of the principal investigator. The rationale for this is that patients of the principal investigator who complete the Feedback form may be biased and this may be reflected in the results.

Oncologist Inclusion Criteria:

1. Oncologists who treat cervix cancer

2. Oncologists with at least one consenting patient enrolled in the study

Oncologist Exclusion Criteria:

1) Principal investigator listed on the protocol. The rationale for this is that oncologists who are also investigators on this study may have inherent bias in the study which may be reflected in the results of the Feedback form.

結果

主な結果の測定

1. Percentage of EORTC QLQ CX24 questionnaire completed [9 months]

Gather information on feasibility of administering questionnaire

2. Percentage of favorable scores (Agree or strongly agree) on Feedback Form [9 months]

Gather information on acceptability of incorporating the questionnaire in routine follow-up

Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge